Gadolinium-Labeled Aminoglycoside and Its Potential Application as a Bacteria-Targeting Magnetic Resonance Imaging...

Area of Science:

• Biomedical Imaging
• Medical Chemistry
• Infectious Disease Diagnostics

Background:

• Magnetic resonance imaging (MRI) offers deep tissue penetration and high spatial resolution without ionizing radiation.
• Diagnosing bacterial infections via MRI is challenging due to a lack of targeted, high-relaxivity contrast agents.
• Existing MRI contrast agents lack specificity for bacterial targets.

Purpose of the Study:

• To develop the first gadolinium-based MRI contrast agent with bacteria-specific targeting capabilities.
• To enhance the in vivo imaging of bacterial infections using MRI.
• To overcome the limitations of current MRI contrast agents in infection detection.

Main Methods:

• Conjugation of neomycin (an aminoglycoside antibiotic) with Dotarem (Gd-DOTA), an FDA-approved MRI contrast agent, to create probe 1.
• Assessment of probe 1's T1 relaxivity compared to Gd-DOTA.
• In vitro cellular studies and preliminary in vivo MRI to evaluate targeting specificity and efficacy against bacteria and macrophage-like cells.

Main Results:

• Probe 1 demonstrated T1 relaxivity comparable to Gd-DOTA.
• Bacteria treated with probe 1 showed a significantly brighter T1-weighted MR signal than those treated with Gd-DOTA.
• In vitro and in vivo studies confirmed probe 1's efficient targeting of bacteria over macrophage-like cells.

Conclusions:

• Probe 1 represents the first gadolinium-based MRI contrast agent specifically designed for bacterial targeting.
• The developed agent shows significant potential for high-resolution in vivo imaging of bacterial infections.
• This advancement could improve the diagnosis and management of bacterial infections using MRI.